Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Antimalarial Adherence is Important for Diabetes Prevention in Lupus
Key clinical point: Adhering to antimalarial treatment protects patients with systemic lupus erythematosus from developing type 2 diabetes mellitus.
Major finding: The adjusted hazard ratio for developing type 2 diabetes mellitus was 0.61 among patients who took at least 90% of their prescribed antimalarial doses, compared with patients who discontinued treatment.
Study details: A retrospective study of 1,498 patients with systemic lupus erythematosus.
Disclosures: The authors reported having no conflicts of interest.
Citation:
Salmasi S et al. Arthritis Care Res. 2020 Jan 21. doi: 10.1002/acr.24147.